Takeda Pharmaceutical Company Company Description
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally.
It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience.
The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands.
It has in-licensing agreements with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaborations with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Institute, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, and Teva Pharmaceutical Industries; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei, Zedira/Dr.
Falk Pharma, Exelixi GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, KM Biologics, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr.
Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics.
The company was founded in 1781 and is headquartered in Tokyo, Japan.
| Country | Japan |
| Founded | 1781 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 47,455 |
| CEO | Christophe Weber |
Contact Details
Address: 1-1, Nihonbashi-Honcho 2-chome Tokyo, 103-8668 Japan | |
| Phone | 81 3 3278-2111 |
| Website | takeda.com |
Stock Details
| Ticker Symbol | TKPHF |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | JPY |
| ISIN Number | JP3463000004 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christophe Weber | President, Chief Executive Officer and Representative Director |
| Milano Furuta | Chief Financial Officer and Director |
| Dr. Andrew S. Plump M.D., Ph.D. | President of Research and Development and Representative Director |
| Dr. Seigo Izumo | Chair of Management Board |
| Haruhiko Hirate | Member of Management Board |
| Salvatore Alesci M.D., Ph.D. | Member of Management Board and Head of Research & Development Global Science and Biomedical Policy |
| Norimasa Takeda | Chief Accounting Officer and Corporate Controller |
| Iwaaki Taniguchi | Senior Vice President of Corporate Finance and Controlling Department |
| Gabriele Ricci | Chief Data and Technology Officer |
| Christopher David O'Reilly | Global Head of Investor Relations and Global Finance |